FBRX vs. KOD, TNXP, CRDF, SOPH, VYGR, YMAB, CRGX, ADCT, SCPH, and NBTX
Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Kodiak Sciences (KOD), Tonix Pharmaceuticals (TNXP), Cardiff Oncology (CRDF), SOPHiA GENETICS (SOPH), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), CARGO Therapeutics (CRGX), ADC Therapeutics (ADCT), scPharmaceuticals (SCPH), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry.
Forte Biosciences vs.
Kodiak Sciences (NASDAQ:KOD) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
Forte Biosciences received 12 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 60.78% of users gave Forte Biosciences an outperform vote while only 26.76% of users gave Kodiak Sciences an outperform vote.
Kodiak Sciences' return on equity of -84.52% beat Forte Biosciences' return on equity.
Kodiak Sciences has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500.
In the previous week, Kodiak Sciences had 5 more articles in the media than Forte Biosciences. MarketBeat recorded 8 mentions for Kodiak Sciences and 3 mentions for Forte Biosciences. Kodiak Sciences' average media sentiment score of 0.35 beat Forte Biosciences' score of 0.08 indicating that Kodiak Sciences is being referred to more favorably in the media.
89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by company insiders. Comparatively, 5.9% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Kodiak Sciences is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
Kodiak Sciences currently has a consensus target price of $9.00, suggesting a potential upside of 153.52%. Forte Biosciences has a consensus target price of $32.50, suggesting a potential upside of 332.18%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Kodiak Sciences.
Summary
Forte Biosciences beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.
Get Forte Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Forte Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:FBRX) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy FBRX Stock Free FBRX Stock Alerts